|
|
EQT Life Sciences, formerly LSP, is one of the world's largest specialized healthcare and biotechnology investment firms. With a history dating back to the late eighties, EQT has grown into a global firm with offices in Amsterdam, Munich and Boston. EQT's investment strategy allows for investments in start-up companies in need of first round venture funding, but also in companies seeking later-stage funding, such as for product development or commercial rollouts. EQT's main areas of focus include drug discovery and development, medical devices, diagnostics, industrial biotech, food & agriculture, and bio materials. Target investee companies typically fall within the EURO 50 million to EURO 1 billion market cap range. EQT's investor base originates from the Benelux, Germany, Switzerland, the UK, the Nordic countries and with a track record going back 30 years, EQT Life Sciences has raised more than €3 billion, and invested in over 150 private companies. Investments per company typically range in size from EURO 10 million up to EURO 60 million over the life of an investment. The firm launched its Euronext-listed EQT Life Sciences Fund in April 2011, with the aim to provide investors with access to the high tech and high growth sector of publicly-traded life sciences companies. In 2017, EQT launched LSP HEF 2 with a fund volume of EUR 280 million targeting investment opportunities in private medical technology companies which offer products that can both improve the quality of patient care and lower healthcare spending.
|
